Genetic Immunology Co., a biopharmaceutical company, plans to list on the Hong Kong Stock Exchange in September.

Market rumour has it that Zhèhùi Biological, a biopharmaceutical company specializing in stem cell drug research and development, plans to list on the Hong Kong Stock Exchange in the third quarter of this year. After several rounds of financing, Zhèhùi Biological has attracted investors including Zhongchuangxin Venture Capital, Jianxin Trust, Guangke Mother Fund, Guoke Jiahe, Zhongshan Torch, Zhengji Capital, Bencao Capital and Shanying Venture Capital.

According to the information, Zhèhùi Biological has already made a layout in the two fields of human embryonic stem cells and induced pluripotent stem cells. The company has international first-class GMP stem cell drug production facilities and complete cell culture and detection facilities. The company has established a sound quality management system for stem cell drugs and successfully carried out process research and quality research on stem cell products, fully meeting the current needs of domestic patients for safe, reliable and high-quality stem cell drugs.

Based on product characteristics, Zhèhùi Biological's product lines include products for the treatment of diseases such as osteonecrosis of the hip and acute respiratory distress syndrome, which currently lack effective treatment methods. Among them, CAStem cell suspension is a self-developed injection product by Zhèhùi Biological, which is composed of immune and matrix regulating cells. The main component of CAStem cell suspension is M-type cells, which are derived from clinical grade human embryonic stem cells. Compared with MSCs, CAStem cell suspension has obvious advantages in terms of purity, uniformity and function.